Prelude Therapeutics Inc
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
175 INNOVATION BOULEVARD, WILMINGTON, DE, 19805
Mailing Address
175 INNOVATION BOULEVARD, WILMINGTON, DE, 19805
Phone
(302) 467-1280
Fiscal Year End
1231
EIN
811384762
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 3 Initial insider ownership report | March 19, 2026 | View on SEC |
| 424B5 Prospectus supplement | March 12, 2026 | View on SEC |
| 8-K Current report of material events | March 12, 2026 | View on SEC |
| 10-K Annual financial report | March 10, 2026 | View on SEC |
| 8-K Current report of material events | March 10, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 13, 2026 | View on SEC |
| 4 Insider stock transaction report | February 5, 2026 | View on SEC |
| 4 Insider stock transaction report | February 5, 2026 | View on SEC |
| 4 Insider stock transaction report | February 5, 2026 | View on SEC |
| 4 Insider stock transaction report | February 5, 2026 | View on SEC |
Annual Reports
10-K
March 10, 2026
- Advanced clinical pipeline with PRT811 in Phase 2 trials for CNS and solid tumors, and Phase 1 for blood cancers.
- Strong internal discovery engine developing diverse small molecule therapies including kinase inhibitors, protein degraders, and ADCs.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.